The objective of this study is to
take the initial steps
toward
developing novel antibiotics to counteract the escalating problem
of antimicrobial and bacterial persistence, particularly in relation
to biofilms. Our approach involves emulating the structural characteristics
of cationic antimicrobial peptides. To circumvent resistance development,
we have designed a library of bis-benzimidazolium salts that selectively
target the microbial membranes in a nonspecific manner. To explore
their structure–activity relationship, we conducted experiments
using these compounds on various pathogens known for their resistance
to conventional antibiotics, including Gram-positive methicillin-resistant
Staphylococcus aureus (MRSA), vancomycin-resistant
Enterococcus faecium (VRE), and Gram-negative Escherichia coli (E. coli). Notably, two bis-benzimidazolium
salts exhibited robust antimicrobial activity while maintaining a
high level of selectivity compared with mammalian cells. Our investigations
revealed significant antibiofilm activity, as these compounds rapidly
acted against established biofilms. In addition, bis-benzimidazolium
compounds exhibited consistent results in resistance development and
cross-resistance studies. Consequently, amphiphilic bis-benzimidazolium
salts hold promise as potential candidates to combat resistance-associated
infections.